Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 2.987
Filtrer
1.
Sci Rep ; 14(1): 15006, 2024 07 01.
Article de Anglais | MEDLINE | ID: mdl-38951583

RÉSUMÉ

Although the relationship between allergies and cancer has been investigated extensively, the role of allergies in head and neck cancer (HNC) appears less consistent. It is unclear whether allergies can independently influence the risk of HNC in the presence of substantial environmental risk factors, including consumption of alcohol, betel quid, and cigarettes. This study aims to find this association. We examined the relationship between allergies and HNC risk in a hospital-based case-control study with 300 cases and 375 matched controls. Logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals, controlling for age, sex, tobacco smoking and opium usage history, alcohol consumption, and socioeconomic status. Our study showed a significant reduction in the risk of HNC associated with allergy symptoms after adjusting for confounders. The risk of HNC was greatly reduced among those with any type of allergy (OR 0.42, 95% CI 0.28, 0.65). The ORs were considerably reduced by 58-88% for different kinds of allergies. The risk of HNC reduction was higher in allergic women than in allergic men (71% vs. 49%). Allergies play an influential role in the risk of HNC development. Future studies investigating immune biomarkers, including cytokine profiles and genetic polymorphisms, are necessary to further delineate the relationship between allergies and HNC. Understanding the relationship between allergies and HNC may help to devise effective strategies to reduce and treat HNC.


Sujet(s)
Tumeurs de la tête et du cou , Hypersensibilité , Humains , Mâle , Femelle , Tumeurs de la tête et du cou/étiologie , Tumeurs de la tête et du cou/épidémiologie , Études cas-témoins , Adulte d'âge moyen , Hypersensibilité/épidémiologie , Hypersensibilité/complications , Facteurs de risque , Sujet âgé , Adulte , Odds ratio
3.
Anticancer Res ; 44(7): 3115-3124, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38925811

RÉSUMÉ

BACKGROUND/AIM: Fine-needle aspiration cytology (FNA) and core needle biopsy (CNB) of the thyroid gland, salivary glands, and lymph nodes are considered simple and rapid methods for minimally invasive tissue collection. We performed a postal survey to analyse the diagnostic value and complication rate of FNA and CNB in Germany. PATIENTS AND METHODS: A questionnaire comprising 11 questions was sent to all 161 German ENT departments in September 2015. RESULTS: The response rate was 45%. In 33 of the 73 responding clinics neither FNA nor CNB were carried out. Of the 26 clinics that provided detailed reasons, the majority (n=18) cited a lack of expertise among the collaborating pathologists. Overall, FNA was used more often, regardless of the anatomical region investigated. The study was based on a total of 36,684 FNAs and 9,624 CNBs. The rate of estimated meaningful and correct findings was 63% (10%-90%) for FNA, and 83% (50%-100%) for CNB. In eight cases (<0.001%) a potential tumor cell spread was reported. CONCLUSION: This is the first nationwide survey in Germany to investigate the utility of FNA and CNB across different localizations in the head and neck region. This study revealed comparable results to the literature regarding the diagnostic value of FNA and CNB. Cell spreading was only observed in individual cases. The appraisal of needle biopsies in the head and neck area seems to be rather inhomogeneous in Germany.


Sujet(s)
Tumeurs de la tête et du cou , Humains , Cytoponction/méthodes , Allemagne/épidémiologie , Tumeurs de la tête et du cou/anatomopathologie , Tumeurs de la tête et du cou/épidémiologie , Tumeurs de la tête et du cou/diagnostic , Biopsie au trocart , Enquêtes et questionnaires , Noeuds lymphatiques/anatomopathologie , Cytologie
4.
Viruses ; 16(6)2024 Jun 03.
Article de Anglais | MEDLINE | ID: mdl-38932197

RÉSUMÉ

HPV16 is responsible for approximately 60% and 90% of global HPV-induced cervical and oropharyngeal cancers, respectively. HPV16 intratype variants have been identified by HPV genome sequencing and classified into four phylogenetic lineages (A-D). Our understanding of HPV16 variants mostly derives from epidemiological studies on cervical cancer (CC) in which HPV16 B, C, and D lineages (previously named "non-European" variants) were mainly associated with high-grade cervical lesions and cancer. Although a predominance of HPV16 lineage A (previously named "European variants") has been observed in head and neck squamous cell carcinoma (HNSCC), epidemiological and in vitro biological studies are still limited for this tumor site. Next Generation Sequencing (NGS) of the entire HPV genome has deepened our knowledge of the prevalence and distribution of HPV variants in CC and HNSCC. Research on cervical cancer has shown that certain HPV16 sublineages, such as D2, D3, A3, and A4, are associated with an increased risk of cervical cancer, and sublineages A4, D2, and D3 are linked to a higher risk of developing adenocarcinomas. Additionally, lineage C and sublineages D2 or D3 of HPV16 show an elevated risk of developing premalignant cervical lesions. However, it is still crucial to conduct large-scale studies on HPV16 variants in different HPV-related tumor sites to deeply evaluate their association with disease development and outcomes. This review discusses the current knowledge and updates on HPV16 phylogenetic variants distribution in HPV-driven anogenital and head and neck cancers.


Sujet(s)
Tumeurs de la tête et du cou , Papillomavirus humain de type 16 , Infections à papillomavirus , Phylogenèse , Humains , Infections à papillomavirus/virologie , Infections à papillomavirus/épidémiologie , Tumeurs de la tête et du cou/virologie , Tumeurs de la tête et du cou/génétique , Tumeurs de la tête et du cou/épidémiologie , Papillomavirus humain de type 16/génétique , Papillomavirus humain de type 16/classification , Femelle , Variation génétique , Tumeurs du col de l'utérus/virologie , Tumeurs du col de l'utérus/épidémiologie , Génome viral , Tumeurs de l'anus/virologie , Tumeurs de l'anus/épidémiologie , Mâle , Carcinome épidermoïde de la tête et du cou/virologie , Carcinome épidermoïde de la tête et du cou/génétique
6.
BMC Infect Dis ; 24(1): 516, 2024 May 23.
Article de Anglais | MEDLINE | ID: mdl-38783184

RÉSUMÉ

BACKGROUND: Human papillomavirus (HPV) is increasingly recognized as a significant risk factor in the development of head and neck cancers (HNCs), with varying prevalence and impact. This study aims to systematically review and analyze the prevalence of HPV in HNCs in India, providing insights into regional variations. METHODS: A comprehensive literature search was carried out using PubMed, Embase, and Web of Science up to November 10, 2023. Inclusion criteria focused on original research reporting HPV-positive cases among HNC patients in India. We used Nested-Knowledge software, for screening, and data extraction. The modified Newcastle-Ottawa Scale was used for quality assessment of included studies. We pooled the prevalence of HPV among HNC patients and performed a random-effects model meta-analysis using R software (version 4.3). RESULTS: The search yielded 33 studies, encompassing 4654 HNC patients. The pooled prevalence of HPV infection was found to be 33% (95% CI: 25.8-42.6), with notable heterogeneity (I² = 95%). Analysis of subgroups according to geographical location indicated varying prevalence rates. Specifically, the prevalence was 47% (95% CI: 32.2-62.4) in the eastern regions and 19.8% (95% CI: 10.8-33.4) in the western regions. No evidence of publication bias was detected. CONCLUSION: The observed considerable regional disparities on the prevalence of HPV in HNC patients in India emphasizes the need for integrated HPV vaccination and screening programs in public health strategies. The findings underline the necessity for further research to explore regional variations and treatment responses in HPV-associated HNCs, considering the impact of factors such as tobacco use and the potential benefits of HPV vaccination.


Sujet(s)
Tumeurs de la tête et du cou , Virus des Papillomavirus humains , Infections à papillomavirus , Femelle , Humains , Mâle , Tumeurs de la tête et du cou/épidémiologie , Tumeurs de la tête et du cou/virologie , Virus des Papillomavirus humains/génétique , Virus des Papillomavirus humains/isolement et purification , Inde/épidémiologie , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Prévalence , Facteurs de risque
7.
Acta Otorhinolaryngol Ital ; 44(3): 169-175, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38712519

RÉSUMÉ

Objective: Despite multiple studies from high-income countries, reports from low- and middle-income countries on the impact of COVID-19 on head and neck cancer care remain sparse. This study aimed to assess the effects of the COVID-19 pandemic on head and neck cancer patients at a tertiary reference centre in Bosnia and Herzegovina. Methods: We included 228 patients with malignant head and neck tumours evaluated and treated between January 1, 2019, and December 31, 2021. Patient demographics, histological characteristics, and treatment modalities were retrospectively obtained and compared between the pre-pandemic period (pre-COVID-19 group) and the period after the implementation of COVID-19 restrictive measures (COVID-19 group). Results: Patients were significantly older during the COVID-19 pandemic. In particular, 63 patients (44.7%) were under 65 and 78 (55.3%) were 65 or older, while in the pre-COVID-19 period, 53 patients (60.9%) were under 65 and 34 (39.1%) were 65 or older (p = 0.017). The pre-COVID-19 and COVID-19 groups did not significantly differ regarding other patient- and tumour characteristics, or primary treatment modalities. Conclusions: During the COVID-19 pandemic, significantly fewer patients were under 65 at the time of initial work-up, potentially reflecting the more enhanced disease-related anxiety of the younger population. Future studies are warranted to address this population's specific educational and psychological needs to ensure appropriate cancer care.


Sujet(s)
COVID-19 , Tumeurs de la tête et du cou , Humains , COVID-19/épidémiologie , Tumeurs de la tête et du cou/thérapie , Tumeurs de la tête et du cou/épidémiologie , Mâle , Femelle , Sujet âgé , Adulte d'âge moyen , Études rétrospectives , Bosnie-et-Herzégovine/épidémiologie , Adulte , Sujet âgé de 80 ans ou plus , Pandémies
9.
Eur Arch Otorhinolaryngol ; 281(8): 4351-4361, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38724856

RÉSUMÉ

BACKGROUND: While treatment advancements have prolonged the lives of patients with head and neck cancer, the subgroups of these patients at higher risk for cardiovascular disease (CVD) mortality remain unclear. METHODS: We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database for patients diagnosed with head and neck cancer from 2000 to 2019. We compared their CVD mortality against the general US population using standardized mortality ratios (SMRs). RESULTS: Our analysis included 474,366 patients, identifying that 14% of deaths were due to CVD, with an SMR of 1.19. Notably, patients under the age of 39 had a CVD SMR increase of over 100-fold. Those with distant tumor stages showed the highest CVD SMR of 1.52 (95% CI 1.50-1.54). An upward trend in SMR to 2.53 (95% CI 2.51-2.56) was observed from 2011 to 2019. Within the initial 5-year post-diagnosis, the SMR for CVD was 3.17 (95% CI 3.14-3.20), which exceeded the general population's rates but declined in the 5-20-year range after diagnosis. Patients who did not any therapy had the greatest CVD SMR of 2.26 (95% CI 2.24-2.28). Hypopharyngeal cancer patients exhibited the highest CVD SMR of 1.54 (95% CI 1.52-1.56). CONCLUSIONS: The study highlights that head and neck cancer patients, especially younger individuals and those with advanced disease stages, face substantial CVD mortality risks. The CVD SMR peaks within 5 years following diagnosis. Patients abstaining from treatment bear the highest risk of CVD mortality. Cardioprotective measures should be considered critical for this patient population.


Sujet(s)
Maladies cardiovasculaires , Tumeurs de la tête et du cou , Programme SEER , Humains , Tumeurs de la tête et du cou/mortalité , Tumeurs de la tête et du cou/épidémiologie , Mâle , Femelle , Maladies cardiovasculaires/mortalité , Maladies cardiovasculaires/épidémiologie , Adulte d'âge moyen , Incidence , Sujet âgé , Adulte , États-Unis/épidémiologie , Sujet âgé de 80 ans ou plus , Facteurs de risque
10.
Nutrients ; 16(10)2024 May 17.
Article de Anglais | MEDLINE | ID: mdl-38794754

RÉSUMÉ

Alcohol consumption significantly impacts disease burden and has been linked to various diseases in observational studies. However, comprehensive meta-analyses using Mendelian randomization (MR) to examine drinking patterns are limited. We aimed to evaluate the health risks of alcohol use by integrating findings from MR studies. A thorough search was conducted for MR studies focused on alcohol exposure. We utilized two sets of instrumental variables-alcohol consumption and problematic alcohol use-and summary statistics from the FinnGen consortium R9 release to perform de novo MR analyses. Our meta-analysis encompassed 64 published and 151 de novo MR analyses across 76 distinct primary outcomes. Results show that a genetic predisposition to alcohol consumption, independent of smoking, significantly correlates with a decreased risk of Parkinson's disease, prostate hyperplasia, and rheumatoid arthritis. It was also associated with an increased risk of chronic pancreatitis, colorectal cancer, and head and neck cancers. Additionally, a genetic predisposition to problematic alcohol use is strongly associated with increased risks of alcoholic liver disease, cirrhosis, both acute and chronic pancreatitis, and pneumonia. Evidence from our MR study supports the notion that alcohol consumption and problematic alcohol use are causally associated with a range of diseases, predominantly by increasing the risk.


Sujet(s)
Consommation d'alcool , Prédisposition génétique à une maladie , Analyse de randomisation mendélienne , Humains , Mâle , Consommation d'alcool/effets indésirables , Consommation d'alcool/génétique , Alcoolisme/génétique , Polyarthrite rhumatoïde/génétique , Tumeurs colorectales/génétique , Tumeurs colorectales/épidémiologie , Tumeurs colorectales/étiologie , Tumeurs de la tête et du cou/génétique , Tumeurs de la tête et du cou/épidémiologie , Maladie de Parkinson/génétique , Maladie de Parkinson/épidémiologie , Maladie de Parkinson/étiologie , Facteurs de risque , Femelle
11.
World J Surg Oncol ; 22(1): 130, 2024 May 16.
Article de Anglais | MEDLINE | ID: mdl-38755616

RÉSUMÉ

BACKGROUND: Many patients with head and neck cancer (HNC) often present with advanced disease. This may result from delay in deciding to seek care, delay in reaching the healthcare facility and or delay in accessing care in the healthcare facility. We therefore set out to determine the time to definitive diagnosis and factors associated with delayed diagnosis among patients with HNC at the Uganda Cancer Institute (UCI). METHODS: A cross-sectional study was conducted at UCI, patients with HNC were recruited. An interviewer administered questionnaire was used to collect data on sociodemographic factors and clinical characteristics, including timelines in months, from symptom onset to deciding to seek care, to reaching the health care facility and to definitive diagnosis. Multivariate Poisson regression analysis was used to calculate odds ratios (ORs) for the factors of association with delayed diagnosis. RESULTS: We recruited 160 HNC patients, and 134 patients were analyzed. The median age was 49.5 years (IQR 26.5), 70% (94 of 134) were male, 48% (69 of 134) had below secondary school education, 49% (65 of 134) had a household income < 54 USD. 56% (76 of 134) were sole bread winners, 67% (89 of 134) had good access road condition to the nearest health unit and 70% (91 of 134) presented with tumor stage 4. Median time from onset of symptoms to definitive diagnosis was 8.1 months (IQR 15.1) and 65% (87 of 134) of patients had delayed diagnosis. Good access roads (aOR: 0.26, p = 0.006), secondary school education (aOR: 0.17, p = 0.038), and household income > 136 USD (aOR: 0.27, p = 0.043) were associated with lower odds of delayed diagnosis. Being the sole bread winner (aOR: 2.15, p = 0.050) increased the odds of delayed diagnosis. CONCLUSION: Most of HNC patients (65%) at UCI had delayed diagnosis. A national care pathway for individuals with suspected HNC should be established and consider rotation of Ear, Nose and Throat surgeons to underserved regions, to mitigate diagnostic delay.


Sujet(s)
Retard de diagnostic , Tumeurs de la tête et du cou , Humains , Mâle , Retard de diagnostic/statistiques et données numériques , Femelle , Études transversales , Adulte d'âge moyen , Ouganda/épidémiologie , Tumeurs de la tête et du cou/diagnostic , Tumeurs de la tête et du cou/épidémiologie , Adulte , Pronostic , Acceptation des soins par les patients/statistiques et données numériques , Études de suivi , Enquêtes et questionnaires/statistiques et données numériques , Accessibilité des services de santé/statistiques et données numériques , Facteurs temps , Sujet âgé
12.
Acta Derm Venereol ; 104: adv18487, 2024 May 17.
Article de Anglais | MEDLINE | ID: mdl-38757177

RÉSUMÉ

An association between psoriasis and cancer risk has been suggested in prior studies, but few have focused on head and neck cancers. Using the Korean National Health Insurance Service database, the relevance between psoriasis and head and neck cancer risks was investigated in a cross-sectional study of 3,869,264 individuals over 20 years of age, who received general health examination in 2009 and were followed until 2020. Head and neck cancer incidence rates were compared between individuals with and without psoriasis, and contributing factors were analysed. The head and neck cancer risk was significantly increased in the psoriasis group compared with the non-psoriasis group (hazard ratio [HR] 1.36; 95% confidence interval [CI] 1.07-1.74; p = 0.01) after adjusting for age, sex, body mass index, income, smoking, alcohol, exercise, diabetes mellitus, hypertension and dyslipidaemia. The risk was especially elevated for nasopharyngeal (HR 2.04; 95% CI 1.12-3.70; p = 0.02) and salivary gland cancer (HR 1.96; 95% CI 1.08-3.56; p = 0.03). Alcohol consumption significantly influenced the risk, particularly for oropharyngeal and oral cavity cancer. Our study provides insights into the potential risks of head and neck cancer in patients with psoriasis, which could aid in refining patient management strategies.


Sujet(s)
Tumeurs de la tête et du cou , Psoriasis , Humains , Psoriasis/épidémiologie , Psoriasis/complications , Mâle , Femelle , Tumeurs de la tête et du cou/épidémiologie , Adulte d'âge moyen , Études transversales , République de Corée/épidémiologie , Facteurs de risque , Adulte , Incidence , Sujet âgé , Appréciation des risques , Bases de données factuelles , Consommation d'alcool/épidémiologie , Consommation d'alcool/effets indésirables , Jeune adulte , Facteurs temps
13.
Respirology ; 29(8): 704-712, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38634359

RÉSUMÉ

BACKGROUND AND OBJECTIVE: Little is known about malignant central airway obstruction (MCAO) complicating the metastatic spread of non-bronchogenic solid cancers (NBC) and their bronchoscopic management. This study aimed to describe the epidemiology of this population and determine prognostic factors before therapeutic bronchoscopy (TB). METHODS: In this multicenter study using the EpiGETIF registry, we analysed patients treated with TB for MCAO caused by NBC between January 2019 and December 2022. RESULTS: From a database of 2389 patients, 436 patients (18%) with MCAO and NBC were identified. After excluding patients with direct local invasion, 214 patients (8.9%) were analysed. The main primaries involved were kidney (17.8%), colon (16.4%), sarcoma (15.4%), thyroid (8.9%) and head and neck (7.9%) cancers. Most patients (63.8%) had already received one or more lines of systemic treatment. Obstructions were purely intrinsic in 58.2%, extrinsic in 11.1% and mixed in 30.8%. Mechanical debulking was used in 73.4% of cases, combined with thermal techniques in 25.6% of cases. Airway stenting was required in 38.4% of patients. Median survival after TB was 11.2 months, influenced by histology (p = 0.002), performance status (p = 0.019), initial hypoxia (HR 1.45 [1.01-2.18]), prior oncologic treatment received (HR 1.82 [1.28-2.56], p < 0.001) and assessment of success at the end of the procedure (HR 0.66 [0.44-0.99], p < 0.001). Complications rate was 8.8%, mostly mild, with no procedure-related mortality. CONCLUSION: TB for MCAO caused by a NBC metastasis provides rapid improvement of symptoms and prolonged survival. Patients should be promptly referred by medical oncologists for bronchoscopic management based on the prognostic factors identified.


Sujet(s)
Obstruction des voies aériennes , Bronchoscopie , Enregistrements , Humains , Bronchoscopie/méthodes , Mâle , Femelle , Obstruction des voies aériennes/étiologie , Obstruction des voies aériennes/épidémiologie , Adulte d'âge moyen , Sujet âgé , Pronostic , Tumeurs de la tête et du cou/complications , Tumeurs de la tête et du cou/épidémiologie , Tumeurs de la tête et du cou/anatomopathologie
14.
J Med Imaging Radiat Oncol ; 68(4): 472-480, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38654618

RÉSUMÉ

INTRODUCTION: The profile and outcomes of head and neck cancer throughout Australia has changed over the past decade. The aim of this study was to perform a population-based analysis of incidence, demographics, stage, treatments and outcomes of patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC), with a particular focus on HPV-associated disease. METHODS: This was a retrospective analysis of prospectively collected data within the Queensland Oncology Repository (QOR) and analysed by the Queensland Cancer Control Analysis Team. The cohort included patients diagnosed in Queensland between 1 January 2015 and 31 December 2019. Outcome measures included incidence of new OPSCC cases, age-standardised rates (ASR) (3-year average), demographics, p16 status, stage (8th Edition American Joint Commission on Cancer), treatments, and 2- and 5-year overall survival. RESULTS: There were 1527 newly diagnosed OPSCC, representing 96% (1527/1584) of all oropharyngeal cancers. It was the most common head and neck cancer diagnosed, with oral cavity cancer being the second most common (n = 1171). Seventy-seven percent were p16 positive (1170/1527), of which 87% (1019/1170) were male. The median age was 61 years and 49% (568/1170) presented with Stage I disease. The ASR was 6.3/100,000, representing a 144% incidence increase since 1982 (2.6/100,000). Radiotherapy was utilised in 91% of p16+ cases with 2- and 5- year overall survival of 89% and 79%, respectively. CONCLUSION: OPSCC is now the most common mucosal head and neck cancer diagnosed in Queensland, having surpassed oral cavity cancer. The majority are HPV-associated (p16+), presenting with early-stage disease with a favourable prognosis.


Sujet(s)
Tumeurs de l'oropharynx , Infections à papillomavirus , Humains , Queensland/épidémiologie , Mâle , Femelle , Adulte d'âge moyen , Tumeurs de l'oropharynx/virologie , Tumeurs de l'oropharynx/épidémiologie , Études rétrospectives , Incidence , Sujet âgé , Stadification tumorale , Adulte , Tumeurs de la tête et du cou/épidémiologie , Sujet âgé de 80 ans ou plus , Taux de survie , Carcinome épidermoïde de la tête et du cou/épidémiologie , Virus des Papillomavirus humains
16.
Am J Otolaryngol ; 45(4): 104300, 2024.
Article de Anglais | MEDLINE | ID: mdl-38640810

RÉSUMÉ

PURPOSE: The experience of long-term pain in head and neck cancer (HNC) survivors is important but has received less attention in the HNC literature. The present study sought to examine the prevalence of pain from 2 to 5 years postdiagnosis and its association with HNC-specific health-related quality of life. MATERIALS & METHODS: Prospective observational study at a single-institution tertiary care center. Pain was measured using a single item ranging from 0 to 10 with 0 representing no pain and 10 representing worst pain possible at 2 through 5 years postdiagnosis. HNC-specific HRQOL was measured using the Head and Neck Cancer Inventory (HNCI). RESULTS: Pain reports were consistent across time. At 2 years postdiagnosis (N = 581), 27.6 % experienced at least some pain with 14.3 % reporting moderate or severe pain. At 3 years postdiagnosis (N = 417), 21.4 % experienced at least some pain with 14.2 % indicating moderate or severe pain. At 4 years postdiagnosis (N = 334), 26.7 % experienced at least some pain with 15.9 % reporting moderate or severe pain. At 5 years postdiagnosis (N = 399), 30.5 % experienced at least some pain with 17.5 % indicating moderate or severe pain. In general, across all four HNCI domains, those in the moderate and severe pain categories largely failed to reach 70 which is indicative of high functioning on the HNCI. CONCLUSIONS: Pain is a considerable issue in long-term HNC survivors up to 5 years postdiagnosis. More research is needed to understand correlates of pain after treatment, including opportunities for screening and intervention, to improve outcomes and optimize recovery in HNC.


Sujet(s)
Survivants du cancer , Tumeurs de la tête et du cou , Qualité de vie , Humains , Tumeurs de la tête et du cou/complications , Tumeurs de la tête et du cou/épidémiologie , Mâle , Femelle , Adulte d'âge moyen , Prévalence , Études prospectives , Survivants du cancer/statistiques et données numériques , Sujet âgé , Facteurs temps , Mesure de la douleur , Adulte , Douleur/épidémiologie , Douleur/étiologie
17.
Eur Arch Otorhinolaryngol ; 281(8): 4341-4350, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38689037

RÉSUMÉ

PURPOSE: Postoperative laryngeal edema (PLE) is a common complication in patients undergoing head and neck surgery, leading to symptoms such as odynophagia, dysphagia, or potential airway obstruction. However, the prevalence and risk factors of PLE in patients undergoing neck dissection (ND) have not been well investigated. METHODS: A retrospective analysis was conducted in three steps. Initially, a pilot study of 50 consecutive ND patients revealed a preliminary PLE prevalence of 0.34. Then, the medical records of an additional 295 ND patients were reviewed to estimate the prevalence of PLE with a total width of 95% confidence interval (CI) of ± 5%. Finally, multivariable logistic regression analyses were performed to identify risk factors for PLE (n = 343). RESULTS: PLE occurred in 29.4% [95%CI 24.4-34.4%] of patients undergoing any type of ND, with the most common symptoms of odynophagia (75.0%) and dyspnea (11.1%). Hospital stay was just one day longer in PLE patients, responding well with short-term steroid treatment (p = 0.0057). In multivariable analyses, no significant association was found between PLE occurrence and airway management. However, body mass index and the American Society of Anesthesiologists classification correlated with PLE. More importantly, surgery for oro-hypopharynx or supraglottis tumors (odds ratio, OR = 3.019, [95%CI 1.166-7.815]) and lymph node level 2(3) ND (OR = 4.214 to 5.279, [95%CI 1.160-20.529]) were significant risk factors for PLE. CONCLUSIONS: PLE developed in approximately 30% of ND patients, causing uncomfortable symptoms. Early diagnosis and intervention of PLE in high-risk patients can improve patient care and outcomes.


Sujet(s)
Oedème laryngé , Évidement ganglionnaire cervical , Complications postopératoires , Humains , Mâle , Femelle , Évidement ganglionnaire cervical/effets indésirables , Facteurs de risque , Adulte d'âge moyen , Études rétrospectives , Oedème laryngé/épidémiologie , Oedème laryngé/étiologie , Complications postopératoires/épidémiologie , Complications postopératoires/étiologie , Prévalence , Sujet âgé , Adulte , Projets pilotes , Tumeurs de la tête et du cou/chirurgie , Tumeurs de la tête et du cou/épidémiologie
18.
Auris Nasus Larynx ; 51(3): 617-622, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38564845

RÉSUMÉ

OBJECTIVE: Previous studies show that the COVID-19 pandemic affected the number of surgeries performed. However, data on the association between the COVID-19 pandemic and otolaryngologic surgeries according to subspecialties are lacking. This study was performed to evaluate the impact of the COVID-19 pandemic on various types of otolaryngologic surgeries. METHODS: We retrospectively identified patients who underwent otolaryngologic surgeries from April 2018 to February 2021 using a Japanese national inpatient database. We performed interrupted time-series analyses before and after April 2020 to evaluate the number of otolaryngologic surgeries performed. The Japanese government declared its first state of emergency during the COVID-19 pandemic in April 2020. RESULTS: We obtained data on 348,351 otolaryngologic surgeries. Interrupted time-series analysis showed a significant decrease in the number of overall otolaryngologic surgeries in April 2020 (-3619 surgeries per month; 95% confidence interval, -5555 to -1683; p < 0.001). Removal of foreign bodies and head and neck cancer surgery were not affected by the COVID-19 pandemic. In the post-COVID-19 period, the number of otolaryngologic surgeries, except for ear and upper airway surgeries, increased significantly. The number of tracheostomies and peritonsillar abscess incisions did not significantly decrease during the COVID-19 pandemic. CONCLUSION: The COVID-19 pandemic was associated with a decrease in the overall number of otolaryngologic surgeries, but the trend differed among subspecialties.


Sujet(s)
COVID-19 , Procédures de chirurgie oto-rhino-laryngologique , Humains , COVID-19/épidémiologie , Japon/épidémiologie , Procédures de chirurgie oto-rhino-laryngologique/statistiques et données numériques , Études rétrospectives , Femelle , Mâle , Adulte d'âge moyen , Sujet âgé , Adulte , SARS-CoV-2 , Analyse de série chronologique interrompue , Tumeurs de la tête et du cou/chirurgie , Tumeurs de la tête et du cou/épidémiologie , Corps étrangers/épidémiologie , Corps étrangers/chirurgie , Enfant , Adolescent
19.
BMC Cancer ; 24(1): 539, 2024 Apr 29.
Article de Anglais | MEDLINE | ID: mdl-38679710

RÉSUMÉ

BACKGROUND: There is no updated national data regarding the real impact of the COVID-19 pandemic on delaying diagnosis and treatment among patients with lung, and head, and neck cancers in Brazil. This study aimed to analyze the COVID-19 pandemic impact on cancer diagnosis and clinical outcomes among lung, head, and neck cancer patients assisted in a tertiary cancer center in Southeastern Brazil, as well as to analyze these patients' pretreatment clinical features. METHODS: Retrospective cohort of patients with lung or head and neck cancer assisted in a tertiary cancer center in southeastern Brazil between January/2019 and December/2021. To assess statistical differences among groups [i.e., cohort 2019 versus (vs.) 2020 and 2019 vs. 2021] chi-square test was used with a 5% significance level and 90% power for sample size calculation. Differences among baseline clinical features and sociodemographic characteristics were evaluated either by T-test for two samples or Fisher's or Pearson's chi-square test (for quantitative or qualitative variables). All utilized tests had a 5% significance level. RESULTS: Six hundred fifty-two patients were included, 332 with lung and 320 with head and neck cancer; it was observed a significant decrease in oncologic treatment recommendations and increase in palliative care recommendation for patients with lung cancer, despite similar stages at diagnosis. During the COVID-19 pandemic, more pain symptoms were reported at the first Oncology assessment for patients with head and neck cancer (p < 0.05). Compared to 2019, head and neck cancer patients diagnosed in 2021 presented a worse initial performance status (p = 0.008). There was a statistically significant increase in survival for patients diagnosed with head and neck cancer in 2021 when compared to 2019 (p = 0.003). CONCLUSIONS: This research highlights low survival rates for patients with lung and head and neck cancer in Brazil, even before the pandemic started, as consequence of advanced diseases at diagnosis at the public health system and clinical degrading features. Additionally, there was an increase incidence in both lung cancer and head and neck cancer despite no differences in clinical stage. This reflects how fragile is the public healthcare system even before facing an acute public health crisis such as the COVID-19 pandemic. Yet, the total impact on public health may follow for many years.


Sujet(s)
COVID-19 , Tumeurs de la tête et du cou , Tumeurs du poumon , Humains , COVID-19/épidémiologie , Brésil/épidémiologie , Tumeurs de la tête et du cou/épidémiologie , Tumeurs de la tête et du cou/thérapie , Tumeurs de la tête et du cou/virologie , Mâle , Femelle , Études rétrospectives , Adulte d'âge moyen , Sujet âgé , Tumeurs du poumon/épidémiologie , Tumeurs du poumon/thérapie , SARS-CoV-2/isolement et purification , Adulte , Soins palliatifs , Sujet âgé de 80 ans ou plus , Retard de diagnostic/statistiques et données numériques , Établissements de cancérologie/statistiques et données numériques
20.
JAMA Otolaryngol Head Neck Surg ; 150(5): 378-384, 2024 May 01.
Article de Anglais | MEDLINE | ID: mdl-38546631

RÉSUMÉ

Importance: Sex differences in head and neck cancer (HNC) incidence suggest a potential contribution of sex hormones. Objective: To assess the role of exogenous estrogen exposure in the development of HNC in female patients. Design, Settings, and Participants: This large multicenter cohort study using clinical records from the TriNetX real-world database included 20 years of data (through May 31, 2023) from 87 health care organizations. The TriNetX database was searched for medical records for female patients with and without exogenous estrogen exposure according to their chronological age. Cohort 1 included 731 366 female patients aged 18 to 45 years old with regular oral contraceptive (OC) intake and cohort 2 included 3 886 568 patients in the same age group who did not use OC. Cohort 3 comprised 135 875 female patients at least 50 years old receiving hormone replacement therapy (HRT), whereas cohort 4 included 5 875 270 patients at least 50 years old without HRT. Propensity score matching was performed for the confounders age, alcohol dependence, and nicotine dependence. Data analyses were performed in May 2023. Main Outcome and Measures: Diagnosis of HNC (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision: C00-C14), and after propensity score matching (1:1 nearest-neighbor greedy matching), a risk analysis to investigate risk differences and risk ratios (RRs) with a 95% CI. Results: Among the 718 101 female patients in each of cohorts 1 and 2 (mean [SD] age at diagnosis, 25.9 [6.7] years), those with OC intake had a higher risk of an HNC diagnosis (RR, 1.47; 95% CI, 1.21-1.78) than those without OC use. Among the 131 835 female patients in each of cohorts 3 and 4 (mean [SD] age, 67.9 [12.0] years), those with postmenopausal HRT intake had a lower risk of an HNC diagnosis (RR, 0.77; 95% CI, 0.64-0.92) than those without HRT use. Conclusions and Relevance: The findings of this cohort study illustrate a positive association between OC and a negative association between HRT and the development of HNC in female patients. Given the limitations of the TriNetX database, future research should include detailed information on the intake of OC and HRT and reproductive health information (eg, age at menarche/menopause, number of pregnancies) to more accurately define the strength and direction of the possible association between exogeneous estrogen exposure and the development of HNC in female patients.


Sujet(s)
Oestrogènes , Tumeurs de la tête et du cou , Humains , Femelle , Adulte d'âge moyen , Adulte , Tumeurs de la tête et du cou/épidémiologie , Oestrogènes/administration et posologie , Oestrogènes/effets indésirables , Adolescent , Oestrogénothérapie substitutive/effets indésirables , Incidence , Études de cohortes , Facteurs de risque , Jeune adulte , Sujet âgé , Score de propension
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE